About Turnstone biologics
Turnstone Biologics: Revolutionizing Cancer Treatment with Viral Immunotherapies
Cancer is one of the most devastating diseases that affect millions of people worldwide. Despite significant advancements in cancer treatment, there is still a need for more effective therapies that can improve patient outcomes and quality of life. Turnstone Biologics is a biotechnology company that aims to revolutionize cancer treatment by developing next-generation viral immunotherapies.
Founded in 2015, Turnstone Biologics has quickly established itself as a leader in the field of viral immunotherapy. The company's mission is to harness the power of viruses to fight cancer and provide patients with better treatment options. With its cutting-edge technology and innovative approach, Turnstone Biologics has attracted top talent from around the world and secured partnerships with leading pharmaceutical companies.
At the heart of Turnstone Biologics' approach is its proprietary platform technology called VacTide™. This technology combines oncolytic viruses (OVs) with tumor-specific T cells to create a powerful immune response against cancer cells. OVs are naturally occurring or genetically modified viruses that selectively infect and kill cancer cells while leaving healthy cells unharmed. Tumor-specific T cells are immune cells that recognize and attack cancer cells based on specific markers or antigens present on their surface.
By combining OVs with tumor-specific T cells, VacTide™ creates a synergistic effect that enhances the immune response against cancer. The OV infects and kills cancer cells, releasing tumor antigens into the bloodstream. These antigens then activate tumor-specific T cells, which recognize and attack any remaining cancerous tissue throughout the body.
Turnstone Biologics' pipeline includes several promising candidates based on its VacTide™ platform technology. The lead candidate, Ad-MG1-MAGEA3, targets MAGE-A3-positive solid tumors such as non-small cell lung carcinoma (NSCLC), melanoma, head-and-neck squamous cell carcinoma (HNSCC), bladder carcinoma (BC), ovarian carcinoma (OC), triple-negative breast carcinoma (TNBC) among others.
Ad-MG1-MAGEA3 has shown promising results in preclinical studies by inducing strong anti-tumor responses without causing significant toxicity or adverse effects in animal models bearing human tumors derived from patients’ samples.
In addition to Ad-MG1-MAGEA3 candidate for solid tumors expressing MAGE-A3 antigen; other candidates include Ad-REP-HSV2 targeting HSV-2 positive cancers such as glioblastoma multiforme(GBM); Ad-REP-CMV targeting CMV positive cancers such as glioblastoma multiforme(GBM); Ad-REP-EBOV targeting Ebola virus glycoprotein-expressing cancers; among others currently under development at various stages including preclinical studies through clinical trials phases I/IIa/IIb/III across multiple indications globally.
Turnstone Biologics' commitment to innovation extends beyond its scientific research efforts; it also includes an unwavering dedication to patient care and advocacy. The company works closely with patient groups and advocates to ensure that its therapies meet their needs while also advocating for policies that support access to innovative treatments for all patients regardless of their socioeconomic status or geographic location.
In conclusion, Turnstone Biologics represents an exciting new frontier in oncology research by harnessing the power of viruses to fight against some types of cancers using novel approaches like VacTide™ platform technology which combines oncolytic viruses(OVs)with tumor-specific T-cells(TSTs). With several promising candidates under development across multiple indications globally including solid tumors expressing MAGE-A3 antigen; HSV-2 positive cancers such as GBM; CMV positive cancers such as GBM; Ebola virus glycoprotein-expressing cancers among others currently under development at various stages including preclinical studies through clinical trials phases I/IIa/IIb/III , this biotech firm could potentially change how we treat certain types of malignancies forever!
turnstonebio.com
